No Data
Press Release: Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Relmada Therapeutics Increases Authorized Shares After Shareholder Vote
Express News | Relmada Therapeutics - Increases Authorized Common Stock to 200 Mln Shares From 150 Mln - SEC Filing
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
152498972 : I chickened out early lost out